ReviewFrontiers in immunology2025
Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- KAT6A inhibitor-loaded and anti-PD-L1-coated manganese metal-organic framework nanoplatform for enhanced colorectal cancer immunotherapy via cGAS-STING activation.International journal of pharmaceutics: X · 2026Article
- Comprehensive Landscape of Diagnostic, Prognostic and Predictive Biomarkers in Colorectal Cancer: From Genomics to Multi-Omics Integration in Precision Medicine.Journal of personalized medicine · 2026Review
- A Glutathione-Responsive Prodrug Nanosystem for Colorectal Cancer: Synergistic Co-Delivery of Paclitaxel and Curcumin to Combat Multidrug Resistance and Reinvent the Immunosuppressive Microenvironment.Biomaterials research · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a prevalent malignancy of the digestive system, with metastatic CRC (mCRC) exhibiting persistently poor overall survival rates. Consequently, there is an urgent need to develop more effective and safer therapeutic strategies. In recent years, immunotherapy has emerged as a groundbreaking approach in CRC treatment. This review highlights the advancements in immune checkpoint Inhibitors (ICIs), cancer vaccines, oncolytic virotherapy, adoptive cell therapy(ACT), and matrix-depletion therapy. Additionally, we explore potential combinatorial immunotherapy strategies for CRC, emphasizing their clinical applications and addressing the challenges associated with CRC immunotherapy. By proposing strategies to overcome these limitations, this review aims to provide novel insights into the evolving landscape of CRC immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.